47
Participants
Start Date
August 16, 2023
Primary Completion Date
December 1, 2026
Study Completion Date
December 31, 2026
FCN-338 + Azacitidine
FCN-338 (400 or 600 mg, PO, QD, D1-28) combined with azacitidine (75mg/m², SC, QD, D1-7), 28 days/cycle
FCN-338 + erythromycin+ Ara-C
"Induction phase: FCN-338(600 mg, QD, D1-14) , erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7) for 1 to 2 cycles.~Consolidation phase: FCN-338(600 mg, QD, D1-14) ,Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles Maintenance phase:FCN-338(600 mg, QD, D1-14) , azacitidine (50 mg/m², SC, QD, D1-5) for the first 12 cycles and FCN-338 (600 mg, QD, D1-14) alone for the rest 12 cycles"
Union hospital tongjimedical college huzhong university of science and technology, Wuhan
Beijing Fosun Pharmaceutical Technology Development Co., Ltd.
UNKNOWN
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
INDUSTRY